Molecular Mechanism of Mutant p53 Stabilization: The Role of HSP70 and MDM2

Abstract

Numerous p53 missense mutations possess gain-of-function activities. Studies in mouse models have demonstrated that the stabilization of p53 R172H (R175H in human) mutant protein, by currently unknown factors, is a prerequisite for its oncogenic gain-of-function phenotype such as tumour progression and metastasis. Here we show that MDM2-dependent ubiquitination and degradation of p53 R175H mutant protein in mouse embryonic fibroblasts is partially inhibited by increasing concentration of heat shock protein 70 (HSP70/HSPA1-A). These phenomena correlate well with the appearance of HSP70-dependent folding intermediates in the form of dynamic cytoplasmic spots containing aggregate-prone p53 R175H and several molecular chaperones. We propose that a transient but recurrent interaction with HSP70 may lead to an increase in mutant p53 protein half-life. In the presence of MDM2 these pseudoaggregates can form stable amyloid-like structures, which occasionally merge into an aggresome. Interestingly, formation of folding intermediates is not observed in the presence of HSC70/HSPA8, the dominant-negative K71S variant of HSP70 or HSP70 inhibitor. In cancer cells, where endogenous HSP70 levels are already elevated, mutant p53 protein forms nuclear aggregates without the addition of exogenous HSP70. Aggregates containing p53 are also visible under conditions where p53 is partially unfolded: 37°C for temperature-sensitive variant p53 V143A and 42°C for wild-type p53. Refolding kinetics of p53 indicate that HSP70 causes transient exposure of p53 aggregate-prone domain(s). We propose that formation of HSP70- and MDM2-dependent protein coaggregates in tumours with high levels of these two proteins could be one of the mechanisms by which mutant p53 is stabilized. Moreover, sequestration of p73 tumour suppressor protein by these nuclear aggregates may lead to gain-of-function phenotypes.

References 89

1. 1.

   Oren M (2003 ) Decision making by p53: life, death and cancer. Cell Death Differ 10: 431–442.

   Not in our library10.1038/sj.cdd.4401183

2. 2.

   Wu X, Bayle JH, Olson D, Levine AJ (1993 ) The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7: 1126–1132.

   Not in our library10.1101/gad.7.7a.1126

3. 3.

   Haupt Y, Maya R, Kazaz A, Oren M (1997 ) Mdm2 promotes the rapid degradation of p53. Nature 387: 296–299.

   Not in our library10.1038/387296a0

4. 4.

   Honda R, Tanaka H, Yasuda H (1997 ) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25–27.

   Not in our library10.1016/s0014-5793(97)01480-4

5. 5.

   Kubbutat MH, Jones SN, Vousden KH (1997 ) Regulation of p53 stability by Mdm2. Nature 387: 299–303.

   Not in our library10.1038/387299a0

6. 6.

   Gajjar M, Candeias MM, Malbert-Colas L, Mazars A, Fujita J, et al (2012 ) The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell 21: 25–35.

   Not in our library10.1016/j.ccr.2011.11.016

7. 7.

   Vogelstein B, Lane D, Levine AJ (2000 ) Surfing the p53 network. Nature 408: 307–310.

   Not in our library10.1038/35042675

8. 8.

   Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, et al (1991 ) Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6: 1699–1703.

   Not in our library

9. 9.

   Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991 ) p53 mutations in human cancers. Science 253: 49–53.

   Not in our library10.1126/science.1905840

10. 10.

    Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, et al (2009 ) Mutant p53 drives invasion by promoting integrin recycling. Cell 139: 1327–1341.

    Not in our library10.1016/j.cell.2009.11.026

11. 11.

    Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, et al (2004 ) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861–872.

    Not in our library10.1016/j.cell.2004.11.006

12. 12.

    Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, et al (2004 ) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847–860.

    Not in our library10.1016/j.cell.2004.11.004

13. 13.

    Blandino G, Levine AJ, Oren M (1999 ) Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18: 477–485.

    Not in our library10.1038/sj.onc.1202314

14. 14.

    Zalcenstein A, Stambolsky P, Weisz L, Muller M, Wallach D, et al (2003 ) Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 22: 5667–5676.

    Not in our library10.1038/sj.onc.1206724

15. 15.

    Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, et al (2004 ) Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res 64: 8318–8327.

    Not in our library10.1158/0008-5472.can-04-1145

16. 16.

    Strano S, Dell’Orso S, Di Agostino S, Fontemaggi G, Sacchi A, et al (2007 ) Mutant p53: an oncogenic transcription factor. Oncogene 26: 2212–2219.

    Not in our library10.1038/sj.onc.1210296

17. 17.

    Maslon MM, Hupp TR (2010 ) Drug discovery and mutant p53. Trends Cell Biol 20: 542–555.

    Not in our library10.1016/j.tcb.2010.06.005

18. 18.

    Muller PA, Vousden KH, Norman JC (2011 ) p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192: 209–218.

    Not in our library10.1083/jcb.201009059

19. 19.

    Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, et al (2000 ) Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 275: 29503–29512.

    Not in our library10.1074/jbc.m003360200

20. 20.

    Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C (2001 ) A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21: 1874–1887.

    Not in our library10.1128/mcb.21.5.1874-1887.2001

21. 21.

    Li Y, Prives C (2007 ) Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 26: 2220–2225.

    Not in our library10.1038/sj.onc.1210311

22. 22.

    Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, et al (2011 ) Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 7: 285–295.

    Not in our library10.1038/nchembio.546

23. 23.

    Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, et al (2007 ) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622–629.

    Not in our library10.1002/humu.20495

24. 24.

    Acin S, Li Z, Mejia O, Roop DR, El-Naggar AK, et al (2011 ) Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. J Pathol 225: 479–489.

    Not in our library10.1002/path.2971

25. 25.

    Trbusek M, Smardova J, Malcikova J, Sebejova L, Dobes P, et al (2011 ) Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol 29: 2703–2708.

    Not in our library10.1200/jco.2011.34.7872

26. 26.

    Lo Nigro C, Vivenza D, Monteverde M, Lattanzio L, Gojis O, et al (2012 ) High frequency of complex TP53 mutations in CNS metastases from breast cancer. Br J Cancer 106: 397–404.

    Not in our library10.1038/bjc.2011.464

27. 27.

    Dai C, Whitesell L, Rogers AB, Lindquist S (2007 ) Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 130: 1005–1018.

    Not in our library10.1016/j.cell.2007.07.020

28. 28.

    King FW, Wawrzynow A, Hohfeld J, Zylicz M (2001 ) Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53. Embo J 20: 6297–6305.

    Not in our library10.1093/emboj/20.22.6297

29. 29.

    Zylicz M, King FW, Wawrzynow A (2001 ) Hsp70 interactions with the p53 tumour suppressor protein. Embo J 20: 4634–4638.

    Not in our library10.1093/emboj/20.17.4634

30. 30.

    Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR (2006 ) Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 31: 164–172.

    Not in our library10.1016/j.tibs.2006.01.006

31. 31.

    Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, et al (2006 ) Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 5: 2592–2601.

    Not in our library10.4161/cc.5.22.3448

32. 32.

    Steiner K, Graf M, Hecht K, Reif S, Rossbacher L, et al (2006 ) High HSP70-membrane expression on leukemic cells from patients with acute myeloid leukemia is associated with a worse prognosis. Leukemia 20: 2076–2079.

    Not in our library10.1038/sj.leu.2404391

33. 33.

    Tsutsumi S, Beebe K, Neckers L (2009 ) Impact of heat-shock protein 90 on cancer metastasis. Future Oncol 5: 679–688.

    Not in our library10.2217/fon.09.30

34. 34.

    Volloch VZ, Sherman MY (1999 ) Oncogenic potential of Hsp72. Oncogene 18: 3648–3651.

    Not in our library10.1038/sj.onc.1202525

35. 35.

    Rohde M, Daugaard M, Jensen MH, Helin K, Nylandsted J, et al (2005 ) Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev 19: 570–582.

    Not in our library10.1101/gad.305405

36. 36.

    Langer T, Lu C, Echols H, Flanagan J, Hayer MK, et al (1992 ) Successive action of DnaK, DnaJ and GroEL along the pathway of chaperone-mediated protein folding. Nature 356: 683–689.

    Not in our library10.1038/356683a0

37. 37.

    Hartl FU, Bracher A, Hayer-Hartl M (2011 ) Molecular chaperones in protein folding and proteostasis. Nature 475: 324–332.

    Not in our library10.1038/nature10317

38. 38.

    Jiang J, Ballinger CA, Wu Y, Dai Q, Cyr DM, et al (2001 ) CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J Biol Chem 276: 42938–42944.

    Not in our library10.1074/jbc.m101968200

39. 39.

    Hohfeld J, Cyr DM, Patterson C (2001 ) From the cradle to the grave: molecular chaperones that may choose between folding and degradation. EMBO Rep 2: 885–890.

    Not in our library10.1093/embo-reports/kve206

40. 40.

    Esser C, Alberti S, Hohfeld J (2004 ) Cooperation of molecular chaperones with the ubiquitin/proteasome system. Biochim Biophys Acta 1695: 171–188.

    Not in our library10.1016/j.bbamcr.2004.09.020

Cited by papers we hold 5

• Targeting p53 pathways: mechanisms, structures and advances in therapy · 2023
  No notice
• Mutant p53: it’s not all one and the same · 2022
  No notice
• Gain-of-function mutant p53 in cancer progression and therapy · 2020
  No notice
• P53 aggregation, interactions with tau, and impaired DNA damage response in Alzheimer’s disease · 2020
  No notice
• Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.